Form 4 for TBPH Theravance Biopharma, Inc.
Accepted 2022-07-27 00:00:00 ET · period of report 2022-07-25 · accession 0001415889-22-008006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-07-27 | 2022-07-25 | TBPH | Hindman Andrew A. | SVP, CFO | A - Grant | $0.00 | +20.0K | 499.2K | +4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-07-25 | A | A | 20,000 | $0.00 | 499,183 | D | — | — | (F1) On July 1, 2019, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a three-year timeframe from 2019 through June 30, 2022 and continued employment. On June 30 2022, the performance conditions applicable to 20,000 shares were achieved and such shares will vest on August 20, 2023, subject to the reporting person's continued service. |